Compare CubeSmart (CUBE) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CubeSmart vs Quest Diagnostics Inc — how do they compare? CubeSmart trades at $40.86 (market cap $9.23B), while Quest Diagnostics Inc trades at $237.51 (market cap $26.23B). The key difference: Quest Diagnostics Inc is far larger — about 2.8× CubeSmart's market cap, and CubeSmart pays the higher dividend (5.17%). Which is the better fit depends on your goals.
| CUBE | DGX | |
|---|---|---|
Market Cap | $9.23B | $26.23B |
Sector | Real Estate | Health |
52-Week High | $42.50 | $238.50 |
52-Week Low | $35.36 | $173.49 |
Enterprise Value | $12.76B | $31.99B |
Dividend Yield | 5.17% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CubeSmart (CUBE) trades at $41.77, down slightly (-0.19%) on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $43.86 offering modest upside. The REIT has demonstrated consistent earnings beats in recent quarters and maintains strong profitability with a 29.41% net income margin. Recent news highlights improving operational trends, including higher occupancy and a raised full-year revenue outlook for 2026, suggesting a potential inflection point.
The outlook is cautiously optimistic, supported by operational momentum and a solid 5% dividend yield. Key risks include a high debt load, with long-term debt of $2.99 billion, and sensitivity to interest rate changes. While analyst sentiment is mixed (44.83% Buy, 51.72% Hold), the stock presents a value opportunity if operational improvements continue, though investors should weigh the debt burden against the stable income profile.
Quest Diagnostics (DGX) trades at $238.35, down slightly by 0.06% today, but maintains a bullish technical trend with strong earnings momentum, having beaten EPS estimates in the last three quarters. Revenue grew to $11.04 billion in 2025, with net income reaching $992 million, and the company raised its 2026 outlook amid surging testing demand. Analyst consensus is a Buy with a $249.50 price target, though valuation multiples like a P/E of 25.3 suggest premium pricing.
The outlook for DGX is positive due to robust demand for diagnostic services, AI integration, and partnerships driving growth, but risks include margin pressure from lower-margin deals and high debt levels. Investors may find opportunity in sustained earnings beats and dividend payouts, yet should monitor competitive and cost pressures that could affect profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
